Trending Topic

11 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Lung cancer is the second most common type of cancer worldwide and in the USA, with its incidence varying depending on geographic and socioeconomic factors.1–3 According to data from the Global Cancer Observatory: Cancer Incidence, Mortality and Prevalence (GLOBACAN) database, an estimated 2.48 million new cases of lung cancer were reported in 2022.4,5 Although lung cancer rates in the […]

Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study

Paolo A Ascierto
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 22nd 2020

Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study.

Questions

  1. What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic melanoma? (0:18)
  2. Could you give us an overview of the aims and design of the SECOMBIT study? (0:57)
  3. What were the major findings of this study and what have they taught us about the optimal sequencing and timing of combination therapy? (3:20)
  4. Could you tell us a little about the ancillary study that will evaluate biomarkers? (5:27)
  5. What future studies are planned? (6:02)

Speaker Disclosures: Dr Paolo A Ascierto discloses the following: Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers-Squibb; Advisory/Consultancy, Research grant/Funding (institution): Roche-Genentech; Advisory/Consultancy, Research grant/Funding (institution): Array; Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy: Novartis; Advisory/Consultancy: Merck Serono; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Incyte; Advisory/Consultancy: Newlink Genetics; Advisory/Consultancy: Genmab; Advisory/Consultancy: MedImmune; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Syndax; Advisory/Consultancy: SunPharma; Advisory/Consultancy: Sanofi; Advisory/Consultancy: Idera; Advisory/Consultancy: Ultimovacs; Advisory/Consultancy: Sandoz; Advisory/Consultancy: Immunocore; Advisory/Consultancy: 4SC; Advisory/Consultancy: Alkermes; Advisory/Consultancy: Italfarmaco; Advisory/Consultancy: Nektar; Advisory/Consultancy: Boehringer-Ingelheim.

Support: Interview and filming supported by Touch Medical Media Ltd. The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study was funded by Bristol Myers Squibb and Array Biopharma

Filmed in coverage of the Virtual 2020 ESMO Congress.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup